Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 81


Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope.

Wolchok JD, Chapman PB.

J Clin Oncol. 2002 Jul 15;20(14):3176; author reply 3176-7. No abstract available.


Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.

Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA.

Cancer Res. 1994 Jun 15;54(12):3124-6. Erratum in: Cancer Res 1994 Jul 15;54(14):3952.


Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy.

Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B.

J Immunol. 2004 Nov 15;173(10):6017-24.


Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.

Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI.

Cancer Res. 2005 Feb 15;65(4):1570-6.


Immunotherapy of melanoma.

Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M.

Semin Cancer Biol. 2003 Dec;13(6):391-400. Review.


Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.

Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A.

Clin Cancer Res. 2004 Aug 15;10(16):5381-90.


Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.

Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G.

J Immunol. 2004 Jan 15;172(2):1304-10.


Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.

Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A.

J Immunother. 2008 Feb-Mar;31(2):215-23. doi: 10.1097/CJI.0b013e3181611420.


Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.

Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL Jr.

J Immunol. 2005 Jun 1;174(11):6863-71.


A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma.

Labarriere N, Fortun A, Bellec A, Khammari A, Dreno B, Saïagh S, Lang F.

Clin Dev Immunol. 2013;2013:932318. doi: 10.1155/2013/932318. Epub 2013 Sep 30.


IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells.

Gabrielsson S, Brichard V, Dhellin O, Dorval T, Bonnerot C.

Anticancer Res. 2004 Jan-Feb;24(1):171-7.


Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients.

Housseau F, Lindsey KR, Oberholtzer SD, Gonzales MI, Boutin P, Moorthy AK, Shankara S, Roberts BL, Topalian SL.

J Immunol Methods. 2002 Aug 1;266(1-2):87-103.


A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients.

Godet Y, Bonnin A, Guilloux Y, Vignard V, Schadendorf D, Dreno B, Jotereau F, Labarriere N.

Cancer Immunol Immunother. 2009 Feb;58(2):271-80. doi: 10.1007/s00262-008-0551-0. Epub 2008 Jul 9.


Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes.

Dadaglio G, Morel S, Bauche C, Moukrim Z, Lemonnier FA, Van Den Eynde BJ, Ladant D, Leclerc C.

Int Immunol. 2003 Dec;15(12):1423-30.


Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.

Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen R, Mackensen A.

J Immunol. 2003 Feb 15;170(4):2161-9.


Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man.

Lotz C, Ferreira EA, Drexler I, Mutallib SA, Huber C, Sutter G, Theobald M.

Int J Cancer. 2004 Feb 10;108(4):571-9.


Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.

Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG.

Cancer Res. 2005 Mar 1;65(5):2009-17.


Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.

Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y, Pandolfino MC, Jotereau F, Dreno B, Labarrière N.

Cancer Immunol Immunother. 2007 Apr;56(4):515-26. Epub 2006 Jul 28.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk